A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Trial ID or NCT#

NCT06777316

Status

recruiting iconRECRUITING

Purpose

This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.

Official Title

A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Lipika Goyal
Medical oncologist
Associate Professor of Medicine (Oncology)
Thomas Holden
Thomas Holden
Medical oncologist
Clinical Assistant Professor, Medicine - Oncology
Steven Corsello
Assistant Professor of Medicine (Oncology) and, by courtesy, of Chemical and Systems Biology
Chris Chen
Chris Chen
Medical oncologist
Assistant Professor of Medicine (Oncology)
George A Fisher
George A Fisher
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine, Emeritus
Shagufta Shaheen
Shagufta Shaheen
Medical oncologist
Clinical Assistant Professor, Medicine - Oncology
Gregory Marshal Heestand
Gregory Marshal Heestand
Medical oncologist, Gastrointestinal specialist
Clinical Associate Professor, Medicine - Oncology
Tyler Johnson
Tyler Johnson
Gastrointestinal specialist, Medical oncologist
Clinical Associate Professor, Medicine - Oncology

Contact us to find out if this trial is right for you.

Contact

GITrial Elegibility

SEND MESSAGE

View on ClinicalTrials.gov